Integrated Wealth Concepts LLC Has $524,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Integrated Wealth Concepts LLC cut its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 36.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,934 shares of the medical research company’s stock after selling 4,556 shares during the period. Integrated Wealth Concepts LLC’s holdings in Edwards Lifesciences were worth $524,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. FSA Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at about $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at about $32,000. Avior Wealth Management LLC raised its holdings in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the period. HHM Wealth Advisors LLC bought a new position in Edwards Lifesciences in the 2nd quarter valued at about $55,000. Finally, Peoples Bank KS bought a new position in Edwards Lifesciences in the 3rd quarter valued at about $40,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $73.41 on Wednesday. The firm has a market cap of $43.29 billion, a PE ratio of 10.59, a price-to-earnings-growth ratio of 3.52 and a beta of 1.12. The firm’s fifty day moving average is $68.75 and its 200-day moving average is $74.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the business earned $0.59 earnings per share. Edwards Lifesciences’s revenue was up 8.9% compared to the same quarter last year. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on EW. Royal Bank of Canada increased their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. Piper Sandler lowered their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Citigroup lowered their target price on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a report on Tuesday, October 1st. Morgan Stanley reaffirmed an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. Finally, Wells Fargo & Company lowered their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $78.35.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 35,000 shares of company stock valued at $2,323,150 over the last quarter. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.